Skip to main navigation Skip to search Skip to main content

Leucine supplementation does not attenuate the decline in daily muscle protein synthesis rates or preserve leg muscle mass during leg immobilization in young or older adults: a double-blind randomized trial

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Background: Muscle disuse leads to muscle atrophy that has been attributed to declines in basal and postprandial muscle protein synthesis (MPS) rates. Leucine regulates MPS and may attenuate disuse-induced declines in MPS rates and muscle mass. Objectives: The purpose of this study was to evaluate the capacity of leucine supplementation to attenuate disuse-induced declines in MPS rates and muscle mass in young and older adults. Methods: In a randomized, double-blind, parallel-group design, 24 young (23 +/- 4 y) and 24 older (69 +/- 4 y) recreationally active adults (equal sex distribution) underwent 3 d of unilateral knee immobilization (leg casting) and received a leucine [group of adult study participants who supplemented with 5 g of leucine 3 & times; daily with each main meal during 3 d of unilateral knee immobilization by means of a full leg cast (LEU)] or energy-matched carbohydrate [group of adult study participants who supplemented with 5 g of carbohydrate 3 & times; daily with each main meal during 3 d of unilateral knee immobilization by means of a full leg cast (PLA)] supplement. Preimmobilization and postimmobilization, quadriceps muscle cross-sectional area (CSA) was assessed in the immobilized (IM) and nonimmobilized (NO-IM) leg by computed tomography. MPS rates were assessed in both legs during immobilization via (H2O)-H-2 coupled with saliva, blood, and muscle biopsy sampling. Results: In young and older adults, MPS rates were similar to 15% and similar to 23% lower in the IM compared with NO-IM leg (1.28 +/- 0.29 compared with 1.50 +/- 0.26 and 1.10 +/- 0.16 compared with 1.46 +/- 0.28%/d, respectively; leg: both P < 0.001), with no differences between LEU compared with PLA treatments (treatment: P = 0.932 and P = 0.742, respectively). CSA decreased by similar to 1.2% and similar to 1.1% in the IM leg in young and older adults (from 7162 +/- 1148 to 7076 +/- 1129 mm(2) and from 5813 +/- 1092 to 5750 +/- 1096 mm(2), respectively; leg & times; time interaction: both P < 0.001), with no differences between LEU compared with PLA (treatment: P = 0.374 and P = 0.998). IM leg MPS rates were lower in older compared with young adults [difference: -0.18 (95% confidence interval: -0.31, -0.04) %/d; P = 0.013]. No differences were observed in the absolute (mm(2)) or relative (%) decline in CSA between young and older adults (both P > 0.05). Conclusions: Leucine supplementation does not attenuate the decline in daily MPS rates or muscle mass during short-term limb immobilization in young or older adults. Clinical Trial Register No. (Netherlands Trial Register): NL-OMON45771.
Original languageEnglish
Article number101205
Number of pages13
JournalAmerican Journal of Clinical Nutrition
Volume123
Issue number4
Early online date1 Feb 2026
DOIs
Publication statusPublished - 1 Apr 2026

Keywords

  • leucine supplementation
  • limb immobilization
  • muscle protein synthesis
  • disuse muscle atrophy
  • skeletal muscle
  • young adults
  • older adults
  • ESSENTIAL AMINO-ACIDS
  • HUMAN QUADRICEPS MUSCLE
  • HUMAN SKELETAL-MUSCLE
  • BED REST
  • ANABOLIC RESISTANCE
  • POSTABSORPTIVE RATS
  • DISUSE ATROPHY
  • LEAN MASS
  • IN-VIVO
  • STIMULATION

Fingerprint

Dive into the research topics of 'Leucine supplementation does not attenuate the decline in daily muscle protein synthesis rates or preserve leg muscle mass during leg immobilization in young or older adults: a double-blind randomized trial'. Together they form a unique fingerprint.

Cite this